Treatment of Cushing’s Disease and Syndrome

  • Dorothy T. Krieger
Part of the Monographs on Endocrinology book series (ENDOCRINOLOGY, volume 22)

Abstract

Cure can be achieved by adrenal extirpation. This is performed by a flank approach, since such tumors are almost always unilateral. Because of the associated atrophy of the contralateral adrenal, patients will require postoperative replacement therapy for a variable time period (3–18 months) until normal adrenocortical function is regained. Cortisol replacement therapy should be maintained at a sufficient dose to avoid symptoms of hypoadrenalism without being so excessive as to prevent recovery of the suppressed pituitary ACTH secretion, which is secondary to the prior hypercortisolism produced by the adenoma. There is no evidence that ACTH treatment to enhance adrenal responsiveness will hasten recovery of such suppressed function,· since recovery at the pituitary level takes a longer time than does that of adrenal responsiveness to ACTH, and the excess Cortisol secretion engendered by such ACTH administration might further delay pituitary recovery.

Keywords

Cholesterol Osteoporosis Cobalt Corticosteroid Dexamethasone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aronin N, Krieger DT (1980) Persistent remission of Nelson’s syndrome following discontinuance of cyproheptadine treatment. N Engl J Med 302:453–455PubMedCrossRefGoogle Scholar
  2. Barnes P, Shaw K, Ross E (1977) Cushing’s disease: Successful treatment with cyproheptadine. Lancet II:1148–1149CrossRefGoogle Scholar
  3. Barzilai D, Dickstein G, Kanter Y, Plavnick Y, Schramek A (1980) Complete remission of Cushing’s disease by total bilateral adrenalectomy and adrenal autotransplantation. J Clin Endocrinol Metab 50:853–856PubMedCrossRefGoogle Scholar
  4. Becker D, Schumacher OP (1975) o,p’DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med 82:677–679PubMedGoogle Scholar
  5. Bennett AH, Cain JP, Dluhy RG, Tynes WV, Harrison JH, Thorn GW (1973) Surgical treatment of adrenocortical hyperplasia: 20-Year experience. J Urol 109:321–324PubMedGoogle Scholar
  6. Bigos ST, Somma M, Rasio E, Eastman RC, Lanthier A, Johnston HH, Hardy J (1980) Cushing’s disease: Management by trans-sphenoidal pituitary microsurgery. J Clin Endocrinol Metab 50:348–354PubMedCrossRefGoogle Scholar
  7. Boyar RM, Witkin M, Carruth A, Ramsey J (1979) Circadian Cortisol secretory rhythms in Cushing’s disease. J Clin Endocrinol Metab 48:760–765PubMedCrossRefGoogle Scholar
  8. Burke CW, Doyle FH, Joplin GF, Arnot RN, MacErlean DP, Fraser TR (1973) Cushing’s disease: Treatment by pituitary implantation of radioactive gold or yttrium seeds. Quart J Med 42:693–714PubMedGoogle Scholar
  9. Carmalt MHB, Dalton GA, Fletcher RF, Smith WT (1977) The treatment of Cushing’s disease by trans-sphenoidal hypophysectomy. Quart J Med 46:119–134PubMedGoogle Scholar
  10. Cassar J, Mashiter K, Joplin GF (1976) Cyproheptadine in Nelson’s syndrome. Lancet III:426CrossRefGoogle Scholar
  11. Child DF, Burke CW, Burley DM, Rees LH, Fraser TR (1976) Drug control of Cushing’s syndrome: Combined aminoglutethimide and metyrapone therapy. Acta Endocrinol 82:330–341PubMedGoogle Scholar
  12. Cope O, Raker JW (1955) Cushing’s disease: The surgical experience in the care of 46 cases. N Engl J Med 253:165–172PubMedCrossRefGoogle Scholar
  13. D’Ercole AJ, Morris MA, Underwood LE, Van Wyk JJ, Feldman JM (1977) Treatment of Cushing’s disease in childhood with cyproheptadine. J Pediatr 90:834–835PubMedCrossRefGoogle Scholar
  14. Dohan FC, Raventos A, Boucot N, Rose E (1957) Roentgen therapy in Cushing’s syndrome without adrenocortical tumor. J Clin Endocrinol Metab 17:8–32PubMedCrossRefGoogle Scholar
  15. Doyle D, O’Donovan DK (1977) More on cyproheptadine in Cushing’s disease. N Engl J Med 296:576CrossRefGoogle Scholar
  16. Ernest I, Ekman H (1972) Adrenalectomy in Cushing’s disease. Acta Endocrinol (Suppl) 160:5–41Google Scholar
  17. Ferrari C, Bertazzoni A, Ghezzi M (1977) Letter to the editor. N Engl J Med 296:576–577CrossRefGoogle Scholar
  18. Fishman LM, Liddle GW, Island DP, Fleischer N, Kuchel O (1967) Effects of aminoglutethimide on adrenal function in man. J Clin Endocrinol Metab 27:481–487PubMedCrossRefGoogle Scholar
  19. Fitzgerald PA, Tyrrell JB, Brooks RM, Forsham PH, Wilson CB (1978) Cushing’s disease: Secondary adrenal insufficiency after selective removal of pituitary tumors. 60th Meeting Endocrine Soc., p 250Google Scholar
  20. Ganong WF (1977) Neurotransmitters involved in ACTH secretion: Catecholamines. In: ACTH and related peptides: Structure, regulation, and action. Ann NY Acad Sci 297:509–516PubMedCrossRefGoogle Scholar
  21. Grant DB, Atherden SM (1979) Cushing’s disease presenting with growth failure: Clinical remission during cyproheptadine therapy. Arch Dis Child 54:466–468PubMedCrossRefGoogle Scholar
  22. Hartwig W, Kasperlik-Zaluska A, Wilczynska J, Migdalaska B (1976) Treatment of Nelson’s syndrome with cyproheptadine. N Engl J Med 295:394CrossRefGoogle Scholar
  23. Heuschele R, Lampe I (1967) Pituitary irradiation for Cushing’s syndrome. Radiol Clin Biol 36:27–31PubMedGoogle Scholar
  24. HÜlhouse EW, Burden J, Jones MT (1975) The effect of various putative neurotransmitters on the release of corticotrophin-releasing hormone from the hypothalamus of the rat in vitro. 1. The effect of acetylcholine and noradrenaline. Neuroendocrinology 17:1–11CrossRefGoogle Scholar
  25. Hutter AM Jr, Kayhoe DE (1966) Adrenal cortical carcinoma: Results of treatment with o,p’DDD in 138 patients. Am J Med 41:581–592PubMedCrossRefGoogle Scholar
  26. Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards CRW, Besser GM (1977) Metyrapone in long-term management of Cushing’s disease. Br Med J II:215–217CrossRefGoogle Scholar
  27. Jennings AS, Liddle GW, Orth DN (1977) Results of treating childhood Cushing’s disease with pituitary irradiation. N Engl J Med 297:957–962PubMedCrossRefGoogle Scholar
  28. Jones MT, Birmingham M, Gillham B, Holmes M, Smith T (1979) The effect of cyproheptadine on the release of corticotrophin-releasing factor. Clin Endocrinol 10:203–204CrossRefGoogle Scholar
  29. Kjellberg RN, Kliman B (1973) A system for therapy of pituitary tumors. In: Kohler PO, Ross GT (eds) Diagnosis and treatment of pituitary tumors. Excerpta Medica, Amsterdam; American Elsevier Publ., New York, pp 234–252Google Scholar
  30. Komanicky P, Spark RF, Melby JC (1978) Treatment of Cushing’s syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J Clin Endocrinol Metab 47:1042–1051PubMedCrossRefGoogle Scholar
  31. Krieger DT (1973) Neurotransmitter regulation of ACTH release. Mt Sinai J Med NY 40:302–314Google Scholar
  32. Krieger DT (1980) Cyproheptadine: Drug therapy for Cushing’s disease. In: Muller EE (ed) Neuroactive drugs in endocrinology. Elsevier/North Holland, Amsterdam, pp 361–370Google Scholar
  33. Krieger DT, Luria M (1976) Effectiveness of cyproheptadine in decreasing plasma ACTH concentrations in Nelson’s syndrome. J Clin Endocrinol Metab 43:1179–1182PubMedCrossRefGoogle Scholar
  34. Krieger DT, Amorosa L, Linick F (1975) Cyproheptadine-induced remission of Cushing’s disease. N Engl J Med 293:893–896PubMedCrossRefGoogle Scholar
  35. Kuwayama A, Kageyama N, Nakane T, Watanabe M, Kanie N (1980) Anterior pituitary function after trans-sphenoidal selective microadenomectomy in Cushing’s disease. VII Int. Cong. Endocrinol., Melbourne, p 385Google Scholar
  36. Lagerquist LG, Meikle AW, West DC, Tyler FH (1974) Cushing’s disease with cure by resection of a pituitary adenoma: Evidence against a primary hypothalamic defect. Am J Med 57:826–830PubMedCrossRefGoogle Scholar
  37. Lamberts SWJ, Klijn JGM, de Quijada M, Timmermans AT, Uitterlinden P, Kirkenhager JC (1980) Bromocriptine and the medical treatment of Cushing’s disease. In: Muller EE (ed). Neuroactive drugs in endocrinology. Elsevier/North Holland, Amsterdam, pp 371–382Google Scholar
  38. Lamberts SWJ, Stefanko SZ, de Lange SA, Fermin H, van der Vijver JCM, Weber RFA, de Jong FH (1980) Failure of clinical remission after trans-sphenoidal removal of a microadenoma in a patient with Cushing’s disease: Multiple hyperplastic and adenomatous cell rests in surrounding pituitary tissue. J Clin Endocrinol Metab 50:793–795PubMedCrossRefGoogle Scholar
  39. Leveston SA, Lee Y-C, Jaffe BM, Daughaday WH (1978) Massive GH and ACTH hypersecretion associated with a metastatic carcinoid tumor. 60th Meeting Endocrine Soc., p 371 (Abstract)Google Scholar
  40. Linfoot JA (1975) Heavy-ion therapy: Alpha-particle therapy of pituitary tumors. In: Linfoot JA (ed) Recent advances in the diagnosis and treatment of pituitary tumors. Raven Press, New York, pp 254–267Google Scholar
  41. Lipsett MB, Hertz R, Ross GT (1963) Clinical and pathophysiologic aspects of adrenocortical carcinoma. Am J Med 35:374–383PubMedCrossRefGoogle Scholar
  42. Lubitz JA, Freeman L, Okun R (1973) Mitotane in operable adrenocortical carcinoma. JAMA. 233:1109–1112CrossRefGoogle Scholar
  43. Ludecke D, Kautzky R, Saeger W, Schrader D (1976) Selective removal of hypersecreting pituitary adenomas? An analysis of endocrine function, operative and microscopical findings in 101 cases. Acta Neurochirurg 35:27–42CrossRefGoogle Scholar
  44. Luton JP, Mahoudeau JA, Bouchard P, Thieblot P, Hautecouverture M, Simon D, Laudat MH, Touitou Y, Bricaire H (1979) Treatment of Cushing’s disease by o,p’DDD: Survey of 62 cases. N Engl J Med 300:459–464PubMedCrossRefGoogle Scholar
  45. MacFarlane DA (1958) Cancer of the adrenal cortex. Ann R Coll Surg 23:155Google Scholar
  46. Marek J, Matys Z, Gregorova L (1977) Cyproheptadine in Cushing’s syndrome. Lancet III: 653–654CrossRefGoogle Scholar
  47. Misbin RI, Canary J, Willard D (1976) Aminoglutethimide in the treatment of Cushing’s syndrome. J Clin Pharmacol 16:645–651PubMedGoogle Scholar
  48. Miura K, Aida M, Mihara A, Kato K, Ojima M, Demura R, Demura H, Okuyama M (1975) Treatment of Cushing’s disease with reserpine and pituitary irradiation. J Clin Endocrinol Metab 41:511–526PubMedCrossRefGoogle Scholar
  49. Moore TJ, Dluhy RG, Williams GH, Cain JP (1976) Nelson’s syndrome: Frequency, prognosis, and effect of prior pituitary irradiation. Ann Intern Med 85:731–734PubMedGoogle Scholar
  50. O’Mullane N, Walker B, Jefferson J, Hipkin L, Diver M, Davis C (1978) Lack of effect of bromocriptine on ACTH levels in patients with bilateral adrenalectomy for pituitary-dependent Cushing’s syndrome. J Endocrinol Invest 1:355–357PubMedGoogle Scholar
  51. Orth DN, Liddle GW (1971) Results of treatment in 108 patients with Cushing’s syndrome. N Engl J Med 285:243–247PubMedCrossRefGoogle Scholar
  52. Ostuni JA, Roginsky MS (1975) Metastatic adrenal cortical carcinoma. Arch Intern Med 135:1257–1258PubMedCrossRefGoogle Scholar
  53. Plotz CM, Knowlton AI, Ragan C (1952) The natural history of Cushing’s syndrome. Am J Med 13:597–614PubMedCrossRefGoogle Scholar
  54. Pont A, Gutierrez-Hartman A (1979) Cushing’s disease: Recurrence after a surgically induced remission. Arch Intern Med 139:938–940PubMedCrossRefGoogle Scholar
  55. Prinz RA, Brooks MH, Lawrence AM, Paloyan E (1979) Cushing’s disease: The role of adrenalectomy and autotransplantation. Surg Clin North Am 59:159–165PubMedGoogle Scholar
  56. Rees LH, Bloomfield GA, Gilkes JJF, Jeffcoate WJ, Besser GM (1977) ACTH as a tumor marker. In: Krieger DT, Ganong WF (eds) ACTH and related peptides: Structure, regulation, and action. NY Acad Sci, New York, pp 603–620Google Scholar
  57. Rovit RL, Duane TD (1969) Cushing’s syndrome and pituitary tumors. Am J Med 46:416–427PubMedCrossRefGoogle Scholar
  58. Salassa RM, Laws ER Jr, Carpenter PC, Northcutt RC (1978) Trans-sphenoidal removal of pituitary microadenoma in Cushing’s disease. Mayo Clin Proc 53:24–28PubMedGoogle Scholar
  59. Schnall AM, Brodkey JS, Kaufman B, Pearson OH (1978) Pituitary function after removal of pituitary microadenomas in Cushing’s disease. J Clin Endocrinol Metab 47:410–417PubMedCrossRefGoogle Scholar
  60. Scott WH Jr, Liddle GW, Mulherin JL Jr, McKenna TJ, Stroup SL, Rhamy RK (1977) Surgical experience with Cushing’s disease. Ann Surg 85:524–534CrossRefGoogle Scholar
  61. Seters van AP, Jenny M, Querido A (1965) Unilateral adrenalectomy followed by pituitary irradiation in Cushing’s disease: With observations on Cortisol secretion after therapy. Acta Endocrinol 48:253–262Google Scholar
  62. Soffer LJ, Iannaccone A, Gabrilove JL (1961) Cushing’s syndrome: A study of 50 patients. Am J Med 30:129–146CrossRefGoogle Scholar
  63. Soyka L (1979) Successful trial of metergoline in juvenile Cushing’s disease (abstract). Pediatr Res 13:385Google Scholar
  64. Tyrrell JB, Brooks RM, Fitzgerald PA, Cofoid PB, Forsham PH, Wilson CB (1978) Selective trans-sphenoidal resection of pituitary microadenomas. N Engl J Med 298:753–758PubMedCrossRefGoogle Scholar
  65. Tyrrell JB, Brooks RM, Forsham PH (1976) More on cyproheptadine. N Engl J Med 295:1137–1138PubMedGoogle Scholar
  66. Walter RM, Ensinck JW, Ricketts H, Kendall JW, Williams RH (1973) Insulin and ACTH production by a streptozotocin-responsive islet cell carcinoma. Am J Med 55:667–670PubMedCrossRefGoogle Scholar
  67. Welbourn RB (1966) Cushing’s syndrome. Scott Med J 11:227–237PubMedGoogle Scholar
  68. Welbourn RB, Montgomery DAD, Kennedy TL (1971) The natural history of treated Cushing’s syndrome. Br J Surg 58:1–16PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin, Heidelberg 1982

Authors and Affiliations

  • Dorothy T. Krieger
    • 1
  1. 1.Division of EndocrinologyThe Mount Sinai Medical CenterNew YorkUSA

Personalised recommendations